Nav: Home

Finding a rhyme and reason to CRISPR-Cas9's mutations

November 07, 2018

Since the early days of CRISPR-Cas9, researchers have known that this gene editing technology is excellent for breaking things. With precision, these scissor-like tools can be sent to any location in the genome to make a snip and break a gene. But exactly where and how CRISPR-Cas9 will disrupt the gene was anyone's guess. Until now. Investigators at Brigham and Women's Hospital, in collaboration with colleagues at the Broad Institute and MIT, have discovered that template-free Cas9 editing is predictable, and they have developed a machine learning model that can predict insertions and deletions with high accuracy. The team, led by co-corresponding authors Richard Sherwood, PhD, David Liu, PhD, and David Gifford, PhD, has demonstrated that this approach can be used to edit and repair mutations related to three diseases in human cell lines -- Hermansky-Pudlak syndrome, Menkes disease and familial hypercholesterolemia - with a predictable repair outcome in more than half of instances. These advancements have implications for both research and clinical applications. The team's findings are published this week in Nature.

"Like many projects, this one came out of a puzzling result: We wanted to use CRISPR-Cas9 to cause a random set of mutations at a particular spot in the genome, but we were finding that the mutations we were getting were far from random," said Sherwood, a principal investigator in the Brigham's Division of Genetics. "It turns out that the underlying sequence to which you are directing CRISPR-Cas9 allows you to predict, with a high degree of accuracy, which mutations you are most likely to get."

Many genetic diseases arise from insertions and deletions that disrupt a gene's function so being able to replicate these or fix them with accuracy would be a major coup. Conventional wisdom among CRISPR-Cas9 researchers has held that the tool randomly generates insertions and deletions in a gene unless researchers include a so-called repair template. But Sherwood's team has found that even without a template, one can predict which insertions and deletions are most likely to occur. At certain genomic sites, one particular mutation dominates - the team used the term "precise-50" to indicate when a single such mutation comprised more than 50 percent of all major editing products.

To conduct their project, Sherwood and colleagues, including Christopher Cassa, PhD, a principal investigator in the Brigham's Division of Genetics, constructed a library of 2,000 Cas9 guide RNAs (gRNAs) paired with DNA target sites. They used this library to train inDelphi, a machine learning model. They found that inDelphi could predict deletions of varying lengths and single base pair insertions with high accuracy (r = 0.87) in five human and mouse cell lines, and that it predicted up to 11 percent of the gRNAs were "precise-50."

To confirm these findings, the team used select gRNAs to correct mutations in cells collected from patients with genetic diseases that result from microduplications - a chromosomal change in which a small amount of genetic material gets duplicated. Hermansky-Pudlak syndrome, especially common in Puerto Ricans, causes blood clotting deficiency and albinism. Menkes disease results in copper deficiency. The team also generated cells with microduplications found in patients to result in familial hypercholesterolemia a disease in which LDL cholesterol levels are abnormally high. For all three diseases, delivering the appropriate Cas9 and guide RNA corrected the mutation with high efficiency.

The authors note that this work is still a proof-of-concept - while promising in cellular models in the lab, it requires further testing and additional steps to bring it into the clinic. In addition, only between 5 and 11 percent of Cas9 guide RNAs met the "precise-50" standard. Sherwood and the team will now work toward optimizing the efficiency of the guide RNAs by understanding why certain insertions or deletions are so much more common than others. They hope that others will leverage the tools they have developed to set regulatory standards for precision in existing therapeutic applications and expand what applications may be possible.

"Currently, most companies that are thinking about therapeutic applications for CRISPR-Cas9 are thinking about what genes you need to break to treat a disease. Our findings indicate that it's possible to predict where we may be able to repair mutations instead," said Sherwood. "We don't want to settle for 50 percent mutation correction - we want to continue to improve. Now that we know that CRISPR-Cas9 editing is predictable, we have a parameter to measure how to fix disease mutations even more precisely."
Funding for this work was provided by an NWO Rubicon Fellowship, NSF Graduate Research Fellowship, DARPA HR0011-17-2-0049, NIHRM1 HG009490L), R01 EB022376, R35 GM118062, HHMI, 1RO1HG008363, 1R01HG008754, 1K01DK101684), the Human Frontier Science Program, NWO, NSF, Brigham Research Institute, Harvard Stem Cell Institute, and American Cancer Society.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.

Brigham and Women's Hospital

Related Genetic Diseases Articles:

Powerful new genomics method can be used to reveal the causes of rare genetic diseases
The technique, which appears in the latest issue of Science, makes use of the fact that people inherit two copies or ''alleles'' of virtually every gene, one from the mother and one from the father.
From centenarians' genetic code, a potential new therapy against cardiovascular diseases
Some people live much longer than average, partly thanks to their DNA.
Summit charts a course to uncover the origins of genetic diseases
A team led by Ivaylo Ivanov of Georgia State University used the 200-petaflop IBM AC922 Summit system, the world's smartest and most powerful supercomputer, to develop an integrative model of the transcription preinitiation complex (PIC), a complex of proteins vital to gene expression.
New screening approach helps identify sources of rare genetic diseases in children
Scientists are using a new approach to pinpoint the causes of rare genetic diseases in children and identify treatment options faster than with traditional methods.
A speedier pipeline to diagnosing genetic diseases in seriously ill infants
Building on previous research, scientists have made improvements to an artificial intelligence pipeline used to diagnose genetic diseases via blood samples obtained from gravely ill infants in a San Diego-based children's hospital.
Researchers use machine-learning system to diagnose genetic diseases
San Diego-Researchers at Rady Children's Institute for Genomic Medicine (RCIGM) have utilized a machine-learning process and clinical natural language processing (CNLP) to diagnose rare genetic diseases in record time.
Rare gut condition a model for study of genetic diseases
A study published online in the April 11, 2019 edition of the New England Journal of Medicine found that Hirschsprung disease is more predictable from an individual's genetic makeup than previously thought.
Selfish genetic elements amplify inflammation and age-related diseases
Researchers from the University of Rochester show that LINE1 retrotransposons, a class of selfish genetic elements, become more active with age and may cause age-related diseases by triggering inflammation.
A common genetic signature has been discovered among three cancer prone rare skin diseases
A group of researchers lead by a lecturer from the Universidad Carlos III de Madrid (UC3M), Marcela del Río, from the CIEMAT, the Rare Diseases Networking Biomedical Research Centre (Initials in Spanish: CIBERER-- ISCIII) and Fundación Jiménez Díaz has identified a common genetic signature among three rare skin diseases or genodermatoses: recessive dystrophic epidermolysis bullosa, Kindler syndrome and xeroderma pigmentosum.
Aging and chronic diseases share genetic factors, study reveals
The study published today in Communications Biology used clinical and genomic data of 300,477 British individuals from UK Biobank to show that the most prevalent chronic conditions such as cancer, diabetes, chronic obstructive pulmonary disease, stroke, dementia, and some others share the common underlying mechanism, that is aging itself, and discover genetic factors associated with healthspan, also known as healthy life expectancy.
More Genetic Diseases News and Genetic Diseases Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.